..unfortunately it seems the Market hates NVAX.
How do you dream this to happen when NVAX has publicly stated they are not meeting with FDA until November?? Please post about the here and now, not your own fantasies.
No question the share price collapse to its current levels is counterintuitive to all the clinical successes that NVAX has reported in the past few months. I think there is concern about Elderly Phase 3 being initiated next month. When and if that happens, the stock should substantially recover. We will know soon!
...down 55% from highs, and 30% from Maternal release. Another few weeks like the last few and everyone will be under water.
No catalysts???....you are clueless....the FDA meeting next month is probably the biggest potential catalyst outside of the RSV Elderly results. If they are given a go with their proposed protocol and endpoints, then 2017 revenues will begin to be factored in to the stock price. Not to mention the very good chance for accelerated approval, as RSV defines the meaning of "unmet medical need". And it could put the stock in play. I do admit that if for whatever reason they don't start the trial next month, more significant downside is coming.
....or this world of hurt will grow larger.
...selling below last Secondary. You would think they had a failed trial instead of multiple successful ones!
They NEED to have good meeting with FDA and start Phase 3 Elderly next month or we get crushed much further. FDA meeting the THE catalyst to turn this around.
If you believe in NVAX then you don't trade it, as that is always a recipe for reduced performance. You hold the stock and wait for the story to play out and the company to realize revenues from RSV Elderly hopefully sometime in 2017. Or a buy out. If either happens, you're looking at a share price significantly higher than $20.00
FDA meeting next month needs to go well and trial to start in November. And FDA agrees with the proposed primary endpoint of the Phase 3 trial, which would give NVAX added likelihood of success in it. Given the tremendous track record of management in executing so far, success seems likely.
In the meantime, we sit with a share price that seems absurdly low.
..First Ebola data - positive. Then Quad Flu data - positive. Then RSV Elderly data - positive. Then Maternal data - controversially positive. Then Pediatric data - positive. And we are selling at close to year to date lows. Biotech collapse is partially responsible, but the fact of the matter is NVAX has substantially unperformed the IBB year to date. Am I misunderstanding the value proposition I believe is here?
I remember the exact same think, and it made me nervous. Now rightfully so. Unreal
All that matters is that NVAX has a good meeting with FDA next month and gets the go ahead to start Elderly Phase 3 in November. Everything else is meaningless at this moment.
...take a look at the 6 or 12 month chart and you'll see the incredible damage that has been done here. This now a sector underperformer.
....5 successful trials, but Maternal killed them, even though results were positive. A very poorly worded press release re. those results set them up for this punishment.
....once again they prove how worthless their journalism is.
...that is critical to the share price. As well as being granted some form of accelerated approval.
Not so sure about that....good article in WSJ the other day regarding the short time span of Biotech bear markets. They traced all the Biotech collapses and rebounds. Bottom line, sell offs are severe but relatively short lived, and rebounds are equally severe.